Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastati
about
Statins for primary prevention of venous thromboembolismStatins for the primary prevention of cardiovascular diseaseStatins for primary prevention of venous thromboembolismRosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspectiveLost in Translation: The Gap in Scientific Advancements and Clinical ApplicationCardiovascular riskManagement of carotid stenosis in women: consensus documentStatins in the primary and secondary prevention of cardiovascular disease in women: facts and mythsDifferences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella reviewCardiovascular Disease in Women: Clinical Perspectives.Novel cardiovascular risk markers in women with ischaemic heart disease.Estrogen implants: embodiments of deeper problems in the marketing of drugs.Differences in the Cardiometabolic Control in Type 2 Diabetes according to Gender and the Presence of Cardiovascular Disease: Results from the eControl Study.Should statin therapy be allocated on the basis of global risk or on the basis of randomized trial evidence?Cranberries and their bioactive constituents in human healthRosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease.Ischaemic heart disease in women: are there sex differences in pathophysiology and risk factors? Position paper from the working group on coronary pathophysiology and microcirculation of the European Society of CardiologyComparison of combined general-epidural anesthesia with general anesthesia effects on survival and cancer recurrence: a meta-analysis of retrospective and prospective studies.The JUPITER lipid lowering trial and vitamin D: Is there a connection?Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22Inflammatory markers in population studies of aging.No connection between the level of exposition to statins in the population and the incidence/mortality of acute myocardial infarction: an ecological study based on Sweden's municipalitiesJUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses.Statin use and risk of diabetes mellitus.Lipoprotein particles and size, total and high molecular weight adiponectin, and leptin in relation to incident coronary heart disease among severely obese postmenopausal women: The Women's Health Initiative Observational Study.Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients.Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins.Relationship between CRP polymorphism and cardiovascular events in Chinese peritoneal dialysis patientsComparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health InitiativeOn-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: aCommunicating statin evidence to support shared decision-making.Dual Effect of Rosuvastatin on Glucose Homeostasis Through Improved Insulin Sensitivity and Reduced Insulin Secretion.A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study.Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA GuidelinesHigh-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities.The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspectiveThe timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 1: comparison of therapeutic efficacy.Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: a population-based register studyStatin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner.Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
P2860
Q24187238-47DF7AE6-6AEC-42F2-9C36-19BE32704BEFQ24201513-E8EFFB88-542A-4232-BBA1-F1C460957A00Q24204040-A12C984D-87EA-40DE-A3CC-48B08CF6F538Q24594814-D12A49AD-E589-40D5-B157-805F0FE68656Q26744789-689DFD25-D928-4AED-9158-533F0083BF55Q26825634-5120197E-FA15-4F16-A55D-8390EA36439EQ26852050-365AC6AF-87AA-41DB-956E-1396F6E5D7C1Q27000723-0BDE0D96-F874-44FF-8F54-7F6579A4014AQ28474985-C2AEDBF9-D18B-4F68-B870-A70A496EACCCQ30743765-44897393-DCA5-4FD4-9DA3-ABA70823ED2DQ33995037-7F91B012-5FDD-4D80-9A6C-67637781EDECQ34050727-127781E6-3155-430C-9345-EE07478ECBB8Q34307460-140AF996-7EEE-4F8C-B38A-A6A5118055C9Q34360294-FB99B4E0-B3D3-4752-A67D-018A09A0FE89Q34384906-2D99C517-725B-45D5-A9AB-0C425C9968C1Q34636887-ED88C5AA-621A-47E1-B807-320B34AF94E7Q34682870-1DE06454-96CC-4F25-BF69-453F0C561891Q34790363-CF3A9E7C-3776-4314-95BB-C22662BB5984Q34847190-EB199847-F060-448B-BE00-3681D8E35290Q34990278-4F4FF615-4147-44FD-8FCF-A952B0FE1089Q34995451-6EC96C39-2D02-418B-9AF3-8A894B993B54Q35081381-F31B75EA-0BB9-4816-8FAB-18EFFC929ADDQ35172886-D1A30928-6451-45CD-A35A-5D83059F3EA6Q35179254-FA4094D9-BDFF-4DB1-B865-198F22B28513Q35221749-652834E5-D271-4506-9666-FC49ED22BC1EQ35233116-F2C31472-9557-4AC9-BD76-9D805CE0B0C1Q35734332-93F9F982-EC47-4097-AFB6-CCB6CF218263Q35758519-A014805F-7E8D-4F26-8A67-45CD057FE69DQ35884178-B3FB3EAB-49E7-41D3-A772-810FE7551788Q35917224-025C2A1F-6715-4C55-B51D-1D6153E5A0DDQ35980419-3C8B47F3-1A5A-44BA-B254-61F0C2C22EEFQ36084295-20D53A43-0D9B-48AC-A585-BD533F2D6AE4Q36543436-3EA4CA05-0561-4409-AC21-65F6DE0BA55BQ36599407-D8D343D5-BC92-478C-B1B0-9F440986305DQ36779288-B641E4AA-2AE5-4620-94D9-16199699DD61Q36781520-0D7F8660-7CA8-454A-B4DD-8A184227AEEFQ36863876-3F92A29F-2A39-4E6A-BFFF-81925706AF1FQ37113316-D6E10757-C4F6-4A8A-88F5-AF2AD18C6D26Q37227150-9E3CACD3-0A2F-4217-95FC-CF412C761AD7Q37279687-C5FA7DB1-4B35-4B3C-ABF6-EA2CCEEEFBD7
P2860
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastati
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Statins for the primary preven ...... n Trial Evaluating Rosuvastati
@ast
Statins for the primary preven ...... n Trial Evaluating Rosuvastati
@en
type
label
Statins for the primary preven ...... n Trial Evaluating Rosuvastati
@ast
Statins for the primary preven ...... n Trial Evaluating Rosuvastati
@en
prefLabel
Statins for the primary preven ...... n Trial Evaluating Rosuvastati
@ast
Statins for the primary preven ...... n Trial Evaluating Rosuvastati
@en
P2093
P2860
P1433
P1476
Statins for the primary preven ...... n Trial Evaluating Rosuvastati
@en
P2093
Jacques Genest
Jean G MacFadyen
Judith Hsia
Paul M Ridker
Robert J Glynn
Samia Mora
P2860
P304
P356
10.1161/CIRCULATIONAHA.109.906479
P407
P577
2010-02-22T00:00:00Z